drugset / Trial / NCT07349472

Pentoxifylline in Patients With Ulcerative Colitis

NCT07349472

Phase 2 Recruiting 60 enrolled Ihab Elsayed Hassan
RandomizedParallel-groupDouble-blindTreatment

Summary

Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.

Timeline

Start
2026-01-20
Primary completion
2027-01-20
Completion
2027-02-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pentoxifylline Small molecule 400 mg
Comparator Mesalamine Small molecule 1 g